Here’s a recent article that shows a promising development for ovarian cancer patients-- wanted to share!
A study on a PARP inhibitor, niraparib, showed that “Niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA mutation status.”
The median progression-free survival for patients given niraparib was 2 years, as opposed to 5.5 months.
PARP inhibitors work by targeting “HRD, a defect in DNA repair that, if unchecked, allows cancer to grow, proliferate, and acquire the biological immortality that characterizes fatal ovarian cancer.”
See the full article here: medpagetoday.com/meetingcov...
